X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse WYETH LTD with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs MYLAN (US) - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WYETH LTD   MYLAN
EQUITY SHARE DATA
    WYETH LTD
Mar-13
MYLAN
Dec-14
WYETH LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0443,867-   
Low Rs8182,725-   
Sales per share (Unadj.) Rs298.61,324.0-  
Earnings per share (Unadj.) Rs57.2159.5-  
Cash flow per share (Unadj.) Rs58.4256.7-  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.5658.1-  
Shares outstanding (eoy) m22.72378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.12.5 125.3%   
Avg P/E ratio x16.320.7 78.7%  
P/CF ratio (eoy) x15.912.8 124.2%  
Price / Book Value ratio x3.75.0 74.5%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1571,247,263 1.7%   
No. of employees `0000.525.0 2.0%   
Total wages/salary Rs m4000-   
Avg. sales/employee Rs Th13,787.420,038.0 68.8%   
Avg. wages/employee Rs Th813.00-   
Avg. net profit/employee Rs Th2,643.32,413.9 109.5%   
INCOME DATA
Net Sales Rs m6,783500,951 1.4%  
Other income Rs m353-2,920 -12.1%   
Total revenues Rs m7,136498,031 1.4%   
Gross profit Rs m1,617124,589 1.3%  
Depreciation Rs m2736,793 0.1%   
Interest Rs m621,608 0.0%   
Profit before tax Rs m1,93863,268 3.1%   
Minority Interest Rs m0-260 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6322,660 23.8%   
Profit after tax Rs m1,30160,348 2.2%  
Gross profit margin %23.824.9 95.9%  
Effective tax rate %32.64.2 775.8%   
Net profit margin %19.212.0 159.1%  
BALANCE SHEET DATA
Current assets Rs m6,984440,402 1.6%   
Current liabilities Rs m2,056344,306 0.6%   
Net working cap to sales %72.619.2 378.7%  
Current ratio x3.41.3 265.6%  
Inventory Days Days9978 127.2%  
Debtors Days Days24107 22.3%  
Net fixed assets Rs m244115,894 0.2%   
Share capital Rs m22717,715 1.3%   
"Free" reserves Rs m5,4410-   
Net worth Rs m5,668249,022 2.3%   
Long term debt Rs m25372,014 0.0%   
Total assets Rs m7,9011,003,037 0.8%  
Interest coverage x353.33.9 8,995.3%   
Debt to equity ratio x01.5 0.3%  
Sales to assets ratio x0.90.5 171.9%   
Return on assets %16.58.2 202.3%  
Return on equity %22.924.2 94.7%  
Return on capital %34.013.6 249.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Net fx Rs m-2,6620-   
CASH FLOW
From Operations Rs m92365,850 1.4%  
From Investments Rs m317-51,931 -0.6%  
From Financial Activity Rs m-481-17,352 2.8%  
Net Cashflow Rs m759-3,433 -22.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare WYETH LTD With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare WYETH LTD With: PANACEA BIOTECH  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS